Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York
New York
10065
United States
203 articles about Memorial Sloan Kettering Cancer Center
-
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
5/18/2023
BeyondSpring Inc. today announced that the Company and Memorial Sloan Kettering Cancer Center (MSK) will present a poster at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 2 through 6 in Chicago, IL.
-
Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs
4/13/2023
Affini-T Therapeutics, Inc today announced a licensing agreement with MSK.
-
Memorial Sloan Kettering researchers present predictive findings from first use of Mission Bio's scMRD assay for AML
9/22/2022
Mission Bio, Inc. announced the first findings by researchers using its new Tapestri® Single-cell Multi-omics Measurable Residual Disease assay, as researchers from Memorial Sloan Kettering Cancer Center discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future acute myeloid leukemia relapse from others present after treatment.
-
Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell TherapiesCertara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies
7/28/2022
Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a 2-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop new biosimulation software. Certara will be working with the MSK Innovation Hub to create a Chimeric antigen receptor (CAR) T-cell therapy biosimulation platform.
-
Repertoire® Immune Medicines Enters New Research Collaboration to Discover the T Cell Response to Therapy in HPV-Associated Cancers
7/14/2022
Repertoire’s DECODE™ technology will be used to identify the specific T cell receptor (TCR) repertoire in early-stag e cancers treated with chemotherapy-radiation and mid- to late-stage cancers treated with anti-PD-1 therapy.
-
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
-
Researchers at the University of California, San Diego published promising preclinical work on a new combination therapy to treat colon cancer.
-
Researchers from all around the world have been working on mapping human genes to their functions. Now, for the first time, that mapping has been completed.
-
In a small study of 14 rectal cancer patients, researchers at Memorial Sloan Kettering Cancer Center published results where 100% of the 12 patients who completed treatment went into remission.
-
The early data demonstrated a favorable safety profile and encouraging indications of clinical activity. BNT122 is being developed in multiple solid tumor indications.
-
Biodesix Announces Research Agreement with Top US Cancer Center
6/3/2022
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it intends to develop a new novel minimal residual disease test as a part of a master sponsored research agreement with Memorial Sloan Kettering Cancer Center.
-
Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center
5/17/2022
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center.
-
Patient enrollment for the clinical trial, which was testing Atara’s autologous chimeric antigen receptor (CAR) T-cell immunology therapy called ATA2271, has been paused.
-
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
-
Here’s a look at 10 of the more compelling research stories of the year.
-
Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors
11/17/2021
Abintus Bio, Inc. today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.
-
Scemblix is the first-in-class FDA-approved treatment for adult patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.
-
Students, Venture Capitalists Launch Equity-Free Program To Support Future Biotech Leaders
9/28/2021
Nucleate, the non-profit organization seeking to support future leaders in the life sciences industry, announced its official launch and immediately opened applications to its Activator program. -
Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and Education
8/2/2021
First-of-its-kind initiative provides patients in India with access to remote opinions and consultations, using technology from India-based telemedicine provider iCliniq
-
Adulhelm's proposed price tag of $56,000 per patient per year is hardly the most expensive drug on the market, but controversy regarding packaging and pricing continues.